vincetan的个人主页 - 老虎社区

vincetan

vincetan

暂无个人介绍

IP属地：未知

69关注

26粉丝

0主题

0勋章

2021-08-01

New leadership means it's either a change to bring the company forward, or vice versa. Hope it's the former!

P&G beats quarterly sales estimates, warns of cost pressures

2021-08-01

$UNI-ASIA GROUP LIMITED(CHJ.SI)$ hope it keeps going up!

2021-07-27

Any thoughts on this?

2021-07-27

$UNI-ASIA GROUP LIMITED(CHJ.SI)$ hope it keeps going up!

2021-07-25

Potential growth!

2021-07-20

Too late to enter?

2021-07-18

Recent sharp increase. Will it keep going up?

2021-07-16

Hope it goes up soon

2021-07-13

Worth buying?

2021-07-13

$Tesla Motors(TSLA)$ keep rising!!

2021-07-12

Still worth buying?

2021-07-12

$Tesla Motors(TSLA)$ still not going up as much as I hope. Keep rising, tesla!

2021-07-09

Agree on the well explained part. //@Cedric77: Great article! Well explained on current down turn.

抱歉，原内容已删除

2021-07-08

The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.

3 Biotechs to Avoid Like the Plague in July

2021-07-08

Worth considering?

2021-07-07

$NIO Inc.(NIO)$ hopefully it goes up!

2021-07-07

Worth considering?

2021-07-07

I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍

40 of the hottest stocks in the market so far in 2021

2021-07-06

The true strength of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!

Jeff Bezos Steps Down as CEO on Monday. Here’s What It Means for Amazon’s Stock.

2021-07-01

$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$ hopefully it keeps going up!

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3583321276956509","uuid":"3583321276956509","gmtCreate":1620229887588,"gmtModify":1622106306048,"name":"vincetan","pinyin":"vincetan","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":26,"headSize":69,"tweetSize":48,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":802868778,"gmtCreate":1627755422494,"gmtModify":1631884081594,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's&nbsp;the former!&nbsp;","listText":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's&nbsp;the former!&nbsp;","text":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's the former!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/802868778","repostId":"2155013045","repostType":4,"repost":{"id":"2155013045","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627642860,"share":"https://ttm.financial/m/news/2155013045?lang=&edition=full","pubTime":"2021-07-30 19:01","market":"us","language":"en","title":"P&G beats quarterly sales estimates, warns of cost pressures","url":"https://stock-news.laohu8.com/highlight/detail?id=2155013045","media":"Reuters","summary":"July 30 (Reuters) - Procter & Gamble Co reported fourth-quarter sales on Friday that beat analysts' ","content":"<p>July 30 (Reuters) - Procter &amp; Gamble Co&nbsp;reported fourth-quarter sales on Friday that beat analysts' estimates, but warned that rising commodity and freight costs would take a $1.9 billion bite out of its earnings this year.</p>\n<p>The vaccine-aided easing of COVID-19 restrictions in the United States and parts of Europe helped the company post an 11% increase in sales at its beauty segment in the reported quarter, as consumers returning to social events, spent more on personal care products.</p>\n<p>Procter &amp; Gamble said net sales rose 7% to $18.95 billion in the quarter ended June 30, compared with estimates of $18.41 billion, according to IBES data from Refinitiv.</p>\n<p>The company forecast fiscal 2022 core earnings per share to rise between 3% and 6%, and sales to increase in the 2% to 4% range.</p>\n<p>Late on Thursday, the Tide detergent maker named Chief Operating Officer Jon Moeller as its new CEO, replacing David Taylor, who will become executive chairman on Nov. 1.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>P&G beats quarterly sales estimates, warns of cost pressures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nP&G beats quarterly sales estimates, warns of cost pressures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-30 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 30 (Reuters) - Procter &amp; Gamble Co&nbsp;reported fourth-quarter sales on Friday that beat analysts' estimates, but warned that rising commodity and freight costs would take a $1.9 billion bite out of its earnings this year.</p>\n<p>The vaccine-aided easing of COVID-19 restrictions in the United States and parts of Europe helped the company post an 11% increase in sales at its beauty segment in the reported quarter, as consumers returning to social events, spent more on personal care products.</p>\n<p>Procter &amp; Gamble said net sales rose 7% to $18.95 billion in the quarter ended June 30, compared with estimates of $18.41 billion, according to IBES data from Refinitiv.</p>\n<p>The company forecast fiscal 2022 core earnings per share to rise between 3% and 6%, and sales to increase in the 2% to 4% range.</p>\n<p>Late on Thursday, the Tide detergent maker named Chief Operating Officer Jon Moeller as its new CEO, replacing David Taylor, who will become executive chairman on Nov. 1.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155013045","content_text":"July 30 (Reuters) - Procter & Gamble Co reported fourth-quarter sales on Friday that beat analysts' estimates, but warned that rising commodity and freight costs would take a $1.9 billion bite out of its earnings this year.\nThe vaccine-aided easing of COVID-19 restrictions in the United States and parts of Europe helped the company post an 11% increase in sales at its beauty segment in the reported quarter, as consumers returning to social events, spent more on personal care products.\nProcter & Gamble said net sales rose 7% to $18.95 billion in the quarter ended June 30, compared with estimates of $18.41 billion, according to IBES data from Refinitiv.\nThe company forecast fiscal 2022 core earnings per share to rise between 3% and 6%, and sales to increase in the 2% to 4% range.\nLate on Thursday, the Tide detergent maker named Chief Operating Officer Jon Moeller as its new CEO, replacing David Taylor, who will become executive chairman on Nov. 1.","news_type":1,"symbols_score_info":{"PG":0.9}},"isVote":1,"tweetType":1,"viewCount":1523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802868411,"gmtCreate":1627755232133,"gmtModify":1631889147563,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHJ.SI\">$UNI-ASIA GROUP LIMITED(CHJ.SI)$</a>&nbsp;hope it keeps going up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHJ.SI\">$UNI-ASIA GROUP LIMITED(CHJ.SI)$</a>&nbsp;hope it keeps going up!&nbsp;","text":"$UNI-ASIA GROUP LIMITED(CHJ.SI)$ hope it keeps going up!","images":[{"img":"https://static.tigerbbs.com/0ec2f15aa488c141b26b753ddbdbf561","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/802868411","isVote":1,"tweetType":1,"viewCount":881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":803068226,"gmtCreate":1627396869965,"gmtModify":1631889147575,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Any thoughts on this?&nbsp;","listText":"Any thoughts on this?&nbsp;","text":"Any thoughts on this?","images":[{"img":"https://static.tigerbbs.com/9f63c2f274fa9680a97f82037443bdbb","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803068226","isVote":1,"tweetType":1,"viewCount":2293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":803084987,"gmtCreate":1627396665749,"gmtModify":1631889147589,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHJ.SI\">$UNI-ASIA GROUP LIMITED(CHJ.SI)$</a>&nbsp;hope it keeps going up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHJ.SI\">$UNI-ASIA GROUP LIMITED(CHJ.SI)$</a>&nbsp;hope it keeps going up!&nbsp;","text":"$UNI-ASIA GROUP LIMITED(CHJ.SI)$ hope it keeps going up!","images":[{"img":"https://static.tigerbbs.com/7d9e3dce81cf36ca5ea821c5be198114","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803084987","isVote":1,"tweetType":1,"viewCount":985,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":177091029,"gmtCreate":1627163772761,"gmtModify":1631889147600,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Potential growth!&nbsp;","listText":"Potential growth!&nbsp;","text":"Potential growth!","images":[{"img":"https://static.tigerbbs.com/1f4204e1d2bbddc38c1e39d2aaca6b78","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/177091029","isVote":1,"tweetType":1,"viewCount":858,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":171151724,"gmtCreate":1626723016068,"gmtModify":1631889147616,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Too late to enter?&nbsp;","listText":"Too late to enter?&nbsp;","text":"Too late to enter?","images":[{"img":"https://static.tigerbbs.com/42219fdf52209378b59da8da9140fbdb","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171151724","isVote":1,"tweetType":1,"viewCount":1835,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":179274848,"gmtCreate":1626544274584,"gmtModify":1631889147627,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Recent sharp increase. Will it keep going up?&nbsp;","listText":"Recent sharp increase. Will it keep going up?&nbsp;","text":"Recent sharp increase. Will it keep going up?","images":[{"img":"https://static.tigerbbs.com/994ed0ff59981c6ffb17b3bbe1d409b6","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179274848","isVote":1,"tweetType":1,"viewCount":1153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":147416764,"gmtCreate":1626381138758,"gmtModify":1631884321251,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Hope it goes up soon","listText":"Hope it goes up soon","text":"Hope it goes up soon","images":[{"img":"https://static.tigerbbs.com/fac2bbd0bfd13c8dd0676d831b606292","width":"1080","height":"3429"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/147416764","isVote":1,"tweetType":1,"viewCount":980,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":145397517,"gmtCreate":1626188961639,"gmtModify":1631889147638,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Worth buying?&nbsp;","listText":"Worth buying?&nbsp;","text":"Worth buying?","images":[{"img":"https://static.tigerbbs.com/59d40da2cb940f58ab55389df62b6753","width":"1080","height":"3429"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145397517","isVote":1,"tweetType":1,"viewCount":1697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":142937900,"gmtCreate":1626118116600,"gmtModify":1631889147652,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;keep rising!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;keep rising!!&nbsp;","text":"$Tesla Motors(TSLA)$ keep rising!!","images":[{"img":"https://static.tigerbbs.com/6088282f18a37677fc335ad1902c4ee6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/142937900","isVote":1,"tweetType":1,"viewCount":1967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148770307,"gmtCreate":1626033424609,"gmtModify":1631889147666,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Still worth buying?&nbsp;","listText":"Still worth buying?&nbsp;","text":"Still worth buying?","images":[{"img":"https://static.tigerbbs.com/8e2c3cf2a30f1a0f5abb76e06c4c04cc","width":"1080","height":"3429"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148770307","isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148770097,"gmtCreate":1626032993819,"gmtModify":1631889147676,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;still not going up as much as I hope. Keep rising, tesla!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;still not going up as much as I hope. Keep rising, tesla!&nbsp;","text":"$Tesla Motors(TSLA)$ still not going up as much as I hope. Keep rising, tesla!","images":[{"img":"https://static.tigerbbs.com/da298c293b298102ce18978879e354d0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148770097","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143417632,"gmtCreate":1625808852926,"gmtModify":1631888361155,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Agree on the well explained part.&nbsp;//<a href=\"https://laohu8.com/U/3575196385895354\">@Cedric77</a>: Great article! Well explained on current down turn.&nbsp;","listText":"Agree on the well explained part.&nbsp;//<a href=\"https://laohu8.com/U/3575196385895354\">@Cedric77</a>: Great article! Well explained on current down turn.&nbsp;","text":"Agree on the well explained part. //@Cedric77: Great article! Well explained on current down turn.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143417632","repostId":"1162204971","repostType":4,"isVote":1,"tweetType":1,"viewCount":447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149876016,"gmtCreate":1625718310035,"gmtModify":1633938032523,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.&nbsp;","listText":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.&nbsp;","text":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/149876016","repostId":"2149365051","repostType":4,"repost":{"id":"2149365051","kind":"highlight","pubTimestamp":1625648700,"share":"https://ttm.financial/m/news/2149365051?lang=&edition=full","pubTime":"2021-07-07 17:05","market":"us","language":"en","title":"3 Biotechs to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=2149365051","media":"Motley Fool","summary":"Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.","content":"<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth.&nbsp;</p>\n<p>Avoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6bccd5c36f3f76148be467937b9b6293\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>1. Cel-Sci</h2>\n<p>Sometimes, <a href=\"https://laohu8.com/S/AONE\">one</a> is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after <a href=\"https://laohu8.com/S/AONE.U\">one</a>'s cover is blown.&nbsp;</p>\n<p>Take the case of&nbsp;<b>Cel-Sci&nbsp;</b>(NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.</p>\n<p>It's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"</p>\n<p>The data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.</p>\n<p>It's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.</p>\n<p>Before the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever).&nbsp;</p>\n<h2>2. CytoDyn&nbsp;</h2>\n<p><b>CytoDyn</b> (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies.&nbsp;</p>\n<p>In response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines.&nbsp;</p>\n<p>It's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.</p>\n<p>I wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.</p>\n<p>At the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders.&nbsp;</p>\n<h2>3. Northwest Biotherapeutics&nbsp;</h2>\n<p><b>Northwest Biotherapeutics</b>&nbsp;(OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies.&nbsp;</p>\n<p>The company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.</p>\n<p>The study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.</p>\n<p>The company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.</p>\n<p>Last October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.</p>\n<p>Shareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotechs to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotechs to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 17:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2149365051","content_text":"Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth. \nAvoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from. \nImage source: Getty Images.\n1. Cel-Sci\nSometimes, one is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after one's cover is blown. \nTake the case of Cel-Sci (NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.\nIt's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"\nThe data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.\nIt's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.\nBefore the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever). \n2. CytoDyn \nCytoDyn (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies. \nIn response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines. \nIt's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.\nI wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.\nAt the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders. \n3. Northwest Biotherapeutics \nNorthwest Biotherapeutics (OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies. \nThe company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.\nThe study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.\nThe company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.\nLast October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.\nShareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.","news_type":1,"symbols_score_info":{"CVM":0.9,"CYDY":0.9,"NWBO":0.9}},"isVote":1,"tweetType":1,"viewCount":430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149870157,"gmtCreate":1625717974079,"gmtModify":1633938035613,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Worth considering?&nbsp;","listText":"Worth considering?&nbsp;","text":"Worth considering?","images":[{"img":"https://static.tigerbbs.com/a4952811b9de8517292610e3b0b8b607","width":"1080","height":"3528"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149870157","isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":157552513,"gmtCreate":1625593929532,"gmtModify":1633939268114,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>&nbsp;hopefully it goes up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>&nbsp;hopefully it goes up!&nbsp;","text":"$NIO Inc.(NIO)$ hopefully it goes up!","images":[{"img":"https://static.tigerbbs.com/cef51ca97f74045e87b17d141370f007","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/157552513","isVote":1,"tweetType":1,"viewCount":653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":157552845,"gmtCreate":1625593895787,"gmtModify":1633939268236,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Worth considering?&nbsp;","listText":"Worth considering?&nbsp;","text":"Worth considering?","images":[{"img":"https://static.tigerbbs.com/eda2526c56441b3a5704779a9ec29d2d","width":"1080","height":"3429"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157552845","isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":157556100,"gmtCreate":1625593693200,"gmtModify":1631889933703,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","listText":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","text":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/157556100","repostId":"2149507863","repostType":4,"repost":{"id":"2149507863","kind":"news","pubTimestamp":1625575839,"share":"https://ttm.financial/m/news/2149507863?lang=&edition=full","pubTime":"2021-07-06 20:50","market":"us","language":"en","title":"40 of the hottest stocks in the market so far in 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2149507863","media":"Yahoo Finance","summary":"It has been a great year for the stock prices of some very well-known companies, and in a few cases ","content":"<p>It has been a great year for the stock prices of some very well-known companies, and in a few cases surprisingly so.</p>\n<p>The broader market's performance hasn't been too shabby, either. So far on the year, the S&amp;P 500 (^GSPC) has rallied 16% — with an 8.5% gain alone in the second quarter. The 40 best-performing stocks in the S&amp;P 500 have notched a median gain of 60.4%, according to data from Goldman Sachs (GS).</p>\n<p>Such double-digit appreciation on the S&amp;P 500 comes despite several formidable headwinds swirling around, ranging from the Archegos Capital Management blowup in the winter to threats of higher taxes from the Biden administration to a clear change in tone on monetary policy from the Federal Reserve.</p>\n<p>The top three best-performing sectors of the S&amp;P 500 include energy (+45%), financials (+25%) and real estate (+24%).</p>\n<p>Underneath the hood of the S&amp;P 500, there have been a host of eye-popping gains as seen below in a new chart out of Goldman Sachs.</p>\n<p>In the not-so-surprising category, there are 69.1% and 49.1% respective increases in the stock prices of Ford (F) and General Motors (GM). Both auto giants have benefited from strong pricing power amid vehicle shortages brought on by the yawning semiconductor shortage. Each has also been praised by Wall Street for aggressive pushes into electric vehicles as they look to challenge EV leader Tesla (TSLA).</p>\n<p>The 53.3% surge in shares of Nvidia also looks to be rather deserved. Analysts have clung onto the chip-maker's stock this year amid strong results for its gaming chips and crypto mining exposure. The impending $40 billion deal for Arm is also seen as a game-changer for the company's future earnings power.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/89d0da979a5704090ea6cfc7522aeb77\" tg-width=\"1794\" tg-height=\"1080\" referrerpolicy=\"no-referrer\"><span>Not too shabby of year for the stock prices of many companies.Goldman Sachs</span></p>\n<p>As for the surprises in the market, there are several that standout.</p>\n<p>For starters, Gap's shares have shot up a mind-bending 68% year to date on optimism over Kanye West's new apparel collection for the retailer and people buying clothes en masse for their post-pandemic lives. But, the company is still seen as a longer term market share loser by most Wall Street analysts.</p>\n<p>Out of the 21 sell-side analysts that cover Gap, only four rate the stock a Buy, according to Bloomberg data. A total of 14 analysts rate the stock a hold, with <a href=\"https://laohu8.com/S/AONE\">one</a> coming in at a sell.</p>\n<p>Wells Fargo (WFC) shares are shockingly up 50.8% this year as new CEO Charlie Scharf struggles to stabilize the company after its highly publicized account fraud scandal. The bank is generally viewed on the Street as not as fundamentally sound as rivals JPMorgan (JPM) and Bank of America (BAC).</p>\n<p>Meanwhile, five of the top 10 best-performing stocks in the S&amp;P 500 this year are energy companies. While the names appear to be tracking the 45% rise in oil prices this year, the gains are somewhat surprising given the increased ESG focus among institutional investors. ExxonMobil is interestingly up 57.9% this year even as it battles through a board shakeup, a bloated cost structure and questions about the leadership of its CEO Darren Woods.</p>\n<p>Whether the S&amp;P 500 could continue its blistering pace evidenced in the first half is anyone's guess. The aforementioned headwinds to stock prices are unlikely going anywhere, and in fact could blow harder, some analysts say.</p>\n<p>\"You've got two big headwinds facing the market in the next six months that I think is likely to restrain the appreciation. The first issue is higher rates [interest]. The idea of higher rates is typically associated with some lower valuations,\" Goldman Sachs chief U.S. equity strategist David Kostin said on Yahoo Finance Live.</p>\n<p>Kostin says the other issue facing investors comes at the hands of lawmakers.</p>\n<p>\"The second issue is tax reform. We are sitting here today literally in the middle of the year and that is likely to be the dominant topic policy-wise in the next several months in Congress as they negotiate both the potential for higher corporate tax rates and the potential for higher capital gains rates,\" Kostin added.</p>\n<p>Kostin's 2021 price target for the S&amp;P 500 is 4,300, a shade below its current level of 4,352.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>40 of the hottest stocks in the market so far in 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n40 of the hottest stocks in the market so far in 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/40-of-the-hottest-stocks-in-the-market-so-far-in-2021-123439153.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It has been a great year for the stock prices of some very well-known companies, and in a few cases surprisingly so.\nThe broader market's performance hasn't been too shabby, either. So far on the year...</p>\n\n<a href=\"https://finance.yahoo.com/news/40-of-the-hottest-stocks-in-the-market-so-far-in-2021-123439153.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/40-of-the-hottest-stocks-in-the-market-so-far-in-2021-123439153.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149507863","content_text":"It has been a great year for the stock prices of some very well-known companies, and in a few cases surprisingly so.\nThe broader market's performance hasn't been too shabby, either. So far on the year, the S&P 500 (^GSPC) has rallied 16% — with an 8.5% gain alone in the second quarter. The 40 best-performing stocks in the S&P 500 have notched a median gain of 60.4%, according to data from Goldman Sachs (GS).\nSuch double-digit appreciation on the S&P 500 comes despite several formidable headwinds swirling around, ranging from the Archegos Capital Management blowup in the winter to threats of higher taxes from the Biden administration to a clear change in tone on monetary policy from the Federal Reserve.\nThe top three best-performing sectors of the S&P 500 include energy (+45%), financials (+25%) and real estate (+24%).\nUnderneath the hood of the S&P 500, there have been a host of eye-popping gains as seen below in a new chart out of Goldman Sachs.\nIn the not-so-surprising category, there are 69.1% and 49.1% respective increases in the stock prices of Ford (F) and General Motors (GM). Both auto giants have benefited from strong pricing power amid vehicle shortages brought on by the yawning semiconductor shortage. Each has also been praised by Wall Street for aggressive pushes into electric vehicles as they look to challenge EV leader Tesla (TSLA).\nThe 53.3% surge in shares of Nvidia also looks to be rather deserved. Analysts have clung onto the chip-maker's stock this year amid strong results for its gaming chips and crypto mining exposure. The impending $40 billion deal for Arm is also seen as a game-changer for the company's future earnings power.\nNot too shabby of year for the stock prices of many companies.Goldman Sachs\nAs for the surprises in the market, there are several that standout.\nFor starters, Gap's shares have shot up a mind-bending 68% year to date on optimism over Kanye West's new apparel collection for the retailer and people buying clothes en masse for their post-pandemic lives. But, the company is still seen as a longer term market share loser by most Wall Street analysts.\nOut of the 21 sell-side analysts that cover Gap, only four rate the stock a Buy, according to Bloomberg data. A total of 14 analysts rate the stock a hold, with one coming in at a sell.\nWells Fargo (WFC) shares are shockingly up 50.8% this year as new CEO Charlie Scharf struggles to stabilize the company after its highly publicized account fraud scandal. The bank is generally viewed on the Street as not as fundamentally sound as rivals JPMorgan (JPM) and Bank of America (BAC).\nMeanwhile, five of the top 10 best-performing stocks in the S&P 500 this year are energy companies. While the names appear to be tracking the 45% rise in oil prices this year, the gains are somewhat surprising given the increased ESG focus among institutional investors. ExxonMobil is interestingly up 57.9% this year even as it battles through a board shakeup, a bloated cost structure and questions about the leadership of its CEO Darren Woods.\nWhether the S&P 500 could continue its blistering pace evidenced in the first half is anyone's guess. The aforementioned headwinds to stock prices are unlikely going anywhere, and in fact could blow harder, some analysts say.\n\"You've got two big headwinds facing the market in the next six months that I think is likely to restrain the appreciation. The first issue is higher rates [interest]. The idea of higher rates is typically associated with some lower valuations,\" Goldman Sachs chief U.S. equity strategist David Kostin said on Yahoo Finance Live.\nKostin says the other issue facing investors comes at the hands of lawmakers.\n\"The second issue is tax reform. We are sitting here today literally in the middle of the year and that is likely to be the dominant topic policy-wise in the next several months in Congress as they negotiate both the potential for higher corporate tax rates and the potential for higher capital gains rates,\" Kostin added.\nKostin's 2021 price target for the S&P 500 is 4,300, a shade below its current level of 4,352.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".SPX":0.9,"BAC":0.6,"F":0.6,"ESmain":0.9,"GM":0.6,"GPS":0.6,"GS":0.9,"IVV":0.9,"JCI":0.6,"JPM":0.6,"LB":0.6,"NVDA":0.6,"NWS":0.9,"NWS.AU":0.6,"NWSA":0.6,"NWSAL":0.6,"NWSLV.AU":0.6,"OEF":0.9,"OEX":0.9,"SDS":0.9,"SH":0.9,"SLB":0.6,"SPXU":0.9,"SPY":0.9,"SSO":0.9,"TSLA":0.6,"UPRO":0.9,"WFC":0.6,"XOM":0.6}},"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154877681,"gmtCreate":1625510334443,"gmtModify":1633940144150,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"The true strength&nbsp;of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!&nbsp;","listText":"The true strength&nbsp;of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!&nbsp;","text":"The true strength of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154877681","repostId":"1157317474","repostType":4,"repost":{"id":"1157317474","kind":"news","pubTimestamp":1625483857,"share":"https://ttm.financial/m/news/1157317474?lang=&edition=full","pubTime":"2021-07-05 19:17","market":"us","language":"en","title":"Jeff Bezos Steps Down as CEO on Monday. Here’s What It Means for Amazon’s Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1157317474","media":"Barrons","summary":"Amazon.com founder Jeff Bezos is stepping down as the company’s CEO on Monday, the company’s 27th birthday. He’s handing over the baton to Andy Jassy, a 24-year Amazon veteran who built and ran Amazon Web Services , the company’s dominant cloud-computing business.As Wall Street analysts like to say, Jassy faces a “tough compare.” Bezos was always going to be a tough act to follow, and he’s leaving the job on top. . Meanwhile, regulatory scrutiny remains a headwind. Amazon is getting considerable","content":"<p>Amazon.com&nbsp;founder Jeff Bezos is stepping down as the company’s CEO on Monday, the company’s 27th birthday. He’s handing over the baton to Andy Jassy, a 24-year Amazon veteran who built and ran Amazon Web Services (AWS), the company’s dominant cloud-computing business.</p>\n<p>As Wall Street analysts like to say, Jassy faces a “tough compare.” Bezos was always going to be a tough act to follow, and he’s leaving the job on top. (He’ll still be executive chairman and the online retailer’s largest shareholder, assuming all goes well with histrip to space later this month.)</p>\n<p>Amazon’s (ticker: AMZN) business sparkled during the pandemic. In the first quarter,sales spiked 44%from a year earlier—the company’s best quarterly growth rate since 2011—and net income was $8.1 billion, its largest quarterly profit ever. With demand surging, Amazon hired more than 500,000 people in 2020, boosting its total staff to more than 1.3 million.</p>\n<p>AWS sales grew 32% in the first quarter, to $13.5 billion, an annualized run rate of well over $50 billion. That makes Amazon one of the world’s largest enterprise computing companies—bigger thanOracle(ORCL),SAP(SAP), orSalesforce.com(CRM). Amazon’s online retail business had revenue of $52.9 billion, up 41%. Third-party seller services like fulfillment and delivery were up 60%, to $23.7 billion (roughly the size ofFedEx). Subscription services, mostly Amazon Prime, had revenue of $7.6 billion, up 36%, for a run rate north of $30 billion (slightly bigger thanNetflix). “Other” revenue—mostly advertising—reached $6.9 billion, up 77%.</p>\n<p>Amazon’s market value is now $1.7 trillion, which trails justApple(AAPL) andMicrosoft(MSFT) among U.S. listed companies.</p>\n<p>Despite the huge numbers, Amazon’s stock has actually looked pedestrian for almost a year now. It’s up just 6% year to date versus 15% for the S&amp;P 500 index. There are several reasons for investor caution, including the CEO turnover. Large tech companies have a mixed record when it comes to replacing founder CEOs.</p>\n<p>The success story is Apple CEO Tim Cook, who took over the top job from Steve Jobs in 2011. Apple shares are up 1,000% since he took over.</p>\n<p>The cautionary tale is Microsoft, where Steve Ballmer succeeded Bill Gates as CEO in January 2000, and stayed in the role for 14 years. Microsoft’s sales tripled with Ballmer at the helm, but the stock went nowhere.</p>\n<p>There are also worries that Amazon’s e-commerce growth could slow as the economy reopens. The challenge for Jassy is to engineer a soft landing—and to drive growth in other areas to offset any e-tail slowdown.</p>\n<p>Meanwhile, regulatory scrutiny remains a headwind. Amazon is getting considerable attention from regulators and legislators for itspending $8.5 billion bid for film studio MGM. Newly appointed Federal Trade Commission Chair Lina Khan has built her career in part byfocusing on Amazon’s market dominance. In 2017, she wrote a now famous Yale Law Review article called “Amazon’s Antitrust Paradox.”</p>\n<p>Last week, Amazon&nbsp;formally asked Khan to recuse herselffrom any involvement in antitrust matters involving the company. Amazon could get its way, but having to ask highlights the risk that regulators now pose.</p>\n<p>The worst case scenario—one reflected in a package of bills under consideration in the U.S. House of Representatives—could force Amazon to shed operations that directly compete with customers, meaning its third-party retailers. That could put an end to Amazon’s ability to sell its own branded products.</p>\n<p>The more subtle risk is that the increased regulatory focus is likely to crimp Amazon’s ability to grow through acquisition. The outcome of the MGM transaction will serve as an important test case.</p>\n<p>Amazon also faces ongoing labor issues even after employees in the company’s Bessemer, Ala., facilityrejected a unionization vote. The company ismaking a big pushto be known as “Earth’s Best Employer” and “Earth’s Safest Place to Work.” Still, Amazon is likely to remain a target for Big Labor. At its annual convention late last month, the Teamsters approved a measure thatsupports a broad unionization push for Amazon’s workforce.</p>\n<p>As for the stock, I’ve noted before that Amazon could be Earth’s Best Stock, especially over the long term. Inmy April 19 column, I pointed to a sum-of-the-parts analysis by Jefferies analyst Brent Thill, which spelled out a $3 trillion market value for Amazon within three years. That estimate includes a projected $1.2 trillion value for AWS, $1 trillion for Amazon’s core retail business, and $600 billion for its ad business. And there are other intriguing bits, like the fast-growing logistics arm and the company’s still-nascent healthcare services unit.</p>\n<p>Even the bearish case on Amazon—a forced breakup—looks bullish when you do the math. If AWS was a stand-alone business and awarded the same sales multiple as red-hot cloud-software companySnowflake(SNOW), AWS would be worth more than $4 trillion. That is certainly ridiculous, but it gives you a sense of the size and power of Amazon’s underlying assets. For long-term investors, Jassy’s Amazon remains an obvious buy.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jeff Bezos Steps Down as CEO on Monday. Here’s What It Means for Amazon’s Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJeff Bezos Steps Down as CEO on Monday. Here’s What It Means for Amazon’s Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 19:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/amazon-ceo-jeff-bezos-andy-jassy-51625253171?siteid=yhoof2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon.com founder Jeff Bezos is stepping down as the company’s CEO on Monday, the company’s 27th birthday. He’s handing over the baton to Andy Jassy, a 24-year Amazon veteran who built and ran Amazon...</p>\n\n<a href=\"https://www.barrons.com/articles/amazon-ceo-jeff-bezos-andy-jassy-51625253171?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/amazon-ceo-jeff-bezos-andy-jassy-51625253171?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157317474","content_text":"Amazon.com founder Jeff Bezos is stepping down as the company’s CEO on Monday, the company’s 27th birthday. He’s handing over the baton to Andy Jassy, a 24-year Amazon veteran who built and ran Amazon Web Services (AWS), the company’s dominant cloud-computing business.\nAs Wall Street analysts like to say, Jassy faces a “tough compare.” Bezos was always going to be a tough act to follow, and he’s leaving the job on top. (He’ll still be executive chairman and the online retailer’s largest shareholder, assuming all goes well with histrip to space later this month.)\nAmazon’s (ticker: AMZN) business sparkled during the pandemic. In the first quarter,sales spiked 44%from a year earlier—the company’s best quarterly growth rate since 2011—and net income was $8.1 billion, its largest quarterly profit ever. With demand surging, Amazon hired more than 500,000 people in 2020, boosting its total staff to more than 1.3 million.\nAWS sales grew 32% in the first quarter, to $13.5 billion, an annualized run rate of well over $50 billion. That makes Amazon one of the world’s largest enterprise computing companies—bigger thanOracle(ORCL),SAP(SAP), orSalesforce.com(CRM). Amazon’s online retail business had revenue of $52.9 billion, up 41%. Third-party seller services like fulfillment and delivery were up 60%, to $23.7 billion (roughly the size ofFedEx). Subscription services, mostly Amazon Prime, had revenue of $7.6 billion, up 36%, for a run rate north of $30 billion (slightly bigger thanNetflix). “Other” revenue—mostly advertising—reached $6.9 billion, up 77%.\nAmazon’s market value is now $1.7 trillion, which trails justApple(AAPL) andMicrosoft(MSFT) among U.S. listed companies.\nDespite the huge numbers, Amazon’s stock has actually looked pedestrian for almost a year now. It’s up just 6% year to date versus 15% for the S&P 500 index. There are several reasons for investor caution, including the CEO turnover. Large tech companies have a mixed record when it comes to replacing founder CEOs.\nThe success story is Apple CEO Tim Cook, who took over the top job from Steve Jobs in 2011. Apple shares are up 1,000% since he took over.\nThe cautionary tale is Microsoft, where Steve Ballmer succeeded Bill Gates as CEO in January 2000, and stayed in the role for 14 years. Microsoft’s sales tripled with Ballmer at the helm, but the stock went nowhere.\nThere are also worries that Amazon’s e-commerce growth could slow as the economy reopens. The challenge for Jassy is to engineer a soft landing—and to drive growth in other areas to offset any e-tail slowdown.\nMeanwhile, regulatory scrutiny remains a headwind. Amazon is getting considerable attention from regulators and legislators for itspending $8.5 billion bid for film studio MGM. Newly appointed Federal Trade Commission Chair Lina Khan has built her career in part byfocusing on Amazon’s market dominance. In 2017, she wrote a now famous Yale Law Review article called “Amazon’s Antitrust Paradox.”\nLast week, Amazon formally asked Khan to recuse herselffrom any involvement in antitrust matters involving the company. Amazon could get its way, but having to ask highlights the risk that regulators now pose.\nThe worst case scenario—one reflected in a package of bills under consideration in the U.S. House of Representatives—could force Amazon to shed operations that directly compete with customers, meaning its third-party retailers. That could put an end to Amazon’s ability to sell its own branded products.\nThe more subtle risk is that the increased regulatory focus is likely to crimp Amazon’s ability to grow through acquisition. The outcome of the MGM transaction will serve as an important test case.\nAmazon also faces ongoing labor issues even after employees in the company’s Bessemer, Ala., facilityrejected a unionization vote. The company ismaking a big pushto be known as “Earth’s Best Employer” and “Earth’s Safest Place to Work.” Still, Amazon is likely to remain a target for Big Labor. At its annual convention late last month, the Teamsters approved a measure thatsupports a broad unionization push for Amazon’s workforce.\nAs for the stock, I’ve noted before that Amazon could be Earth’s Best Stock, especially over the long term. Inmy April 19 column, I pointed to a sum-of-the-parts analysis by Jefferies analyst Brent Thill, which spelled out a $3 trillion market value for Amazon within three years. That estimate includes a projected $1.2 trillion value for AWS, $1 trillion for Amazon’s core retail business, and $600 billion for its ad business. And there are other intriguing bits, like the fast-growing logistics arm and the company’s still-nascent healthcare services unit.\nEven the bearish case on Amazon—a forced breakup—looks bullish when you do the math. If AWS was a stand-alone business and awarded the same sales multiple as red-hot cloud-software companySnowflake(SNOW), AWS would be worth more than $4 trillion. That is certainly ridiculous, but it gives you a sense of the size and power of Amazon’s underlying assets. For long-term investors, Jassy’s Amazon remains an obvious buy.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158539514,"gmtCreate":1625154535338,"gmtModify":1631888920994,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>&nbsp;hopefully it keeps going up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>&nbsp;hopefully it keeps going up!&nbsp;","text":"$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$ hopefully it keeps going up!","images":[{"img":"https://static.tigerbbs.com/6c1bd42cf964b85c81960a4e99156b8b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158539514","isVote":1,"tweetType":1,"viewCount":454,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":157556100,"gmtCreate":1625593693200,"gmtModify":1631889933703,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","listText":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","text":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/157556100","repostId":"2149507863","repostType":4,"repost":{"id":"2149507863","kind":"news","pubTimestamp":1625575839,"share":"https://ttm.financial/m/news/2149507863?lang=&edition=full","pubTime":"2021-07-06 20:50","market":"us","language":"en","title":"40 of the hottest stocks in the market so far in 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2149507863","media":"Yahoo Finance","summary":"It has been a great year for the stock prices of some very well-known companies, and in a few cases ","content":"<p>It has been a great year for the stock prices of some very well-known companies, and in a few cases surprisingly so.</p>\n<p>The broader market's performance hasn't been too shabby, either. So far on the year, the S&amp;P 500 (^GSPC) has rallied 16% — with an 8.5% gain alone in the second quarter. The 40 best-performing stocks in the S&amp;P 500 have notched a median gain of 60.4%, according to data from Goldman Sachs (GS).</p>\n<p>Such double-digit appreciation on the S&amp;P 500 comes despite several formidable headwinds swirling around, ranging from the Archegos Capital Management blowup in the winter to threats of higher taxes from the Biden administration to a clear change in tone on monetary policy from the Federal Reserve.</p>\n<p>The top three best-performing sectors of the S&amp;P 500 include energy (+45%), financials (+25%) and real estate (+24%).</p>\n<p>Underneath the hood of the S&amp;P 500, there have been a host of eye-popping gains as seen below in a new chart out of Goldman Sachs.</p>\n<p>In the not-so-surprising category, there are 69.1% and 49.1% respective increases in the stock prices of Ford (F) and General Motors (GM). Both auto giants have benefited from strong pricing power amid vehicle shortages brought on by the yawning semiconductor shortage. Each has also been praised by Wall Street for aggressive pushes into electric vehicles as they look to challenge EV leader Tesla (TSLA).</p>\n<p>The 53.3% surge in shares of Nvidia also looks to be rather deserved. Analysts have clung onto the chip-maker's stock this year amid strong results for its gaming chips and crypto mining exposure. The impending $40 billion deal for Arm is also seen as a game-changer for the company's future earnings power.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/89d0da979a5704090ea6cfc7522aeb77\" tg-width=\"1794\" tg-height=\"1080\" referrerpolicy=\"no-referrer\"><span>Not too shabby of year for the stock prices of many companies.Goldman Sachs</span></p>\n<p>As for the surprises in the market, there are several that standout.</p>\n<p>For starters, Gap's shares have shot up a mind-bending 68% year to date on optimism over Kanye West's new apparel collection for the retailer and people buying clothes en masse for their post-pandemic lives. But, the company is still seen as a longer term market share loser by most Wall Street analysts.</p>\n<p>Out of the 21 sell-side analysts that cover Gap, only four rate the stock a Buy, according to Bloomberg data. A total of 14 analysts rate the stock a hold, with <a href=\"https://laohu8.com/S/AONE\">one</a> coming in at a sell.</p>\n<p>Wells Fargo (WFC) shares are shockingly up 50.8% this year as new CEO Charlie Scharf struggles to stabilize the company after its highly publicized account fraud scandal. The bank is generally viewed on the Street as not as fundamentally sound as rivals JPMorgan (JPM) and Bank of America (BAC).</p>\n<p>Meanwhile, five of the top 10 best-performing stocks in the S&amp;P 500 this year are energy companies. While the names appear to be tracking the 45% rise in oil prices this year, the gains are somewhat surprising given the increased ESG focus among institutional investors. ExxonMobil is interestingly up 57.9% this year even as it battles through a board shakeup, a bloated cost structure and questions about the leadership of its CEO Darren Woods.</p>\n<p>Whether the S&amp;P 500 could continue its blistering pace evidenced in the first half is anyone's guess. The aforementioned headwinds to stock prices are unlikely going anywhere, and in fact could blow harder, some analysts say.</p>\n<p>\"You've got two big headwinds facing the market in the next six months that I think is likely to restrain the appreciation. The first issue is higher rates [interest]. The idea of higher rates is typically associated with some lower valuations,\" Goldman Sachs chief U.S. equity strategist David Kostin said on Yahoo Finance Live.</p>\n<p>Kostin says the other issue facing investors comes at the hands of lawmakers.</p>\n<p>\"The second issue is tax reform. We are sitting here today literally in the middle of the year and that is likely to be the dominant topic policy-wise in the next several months in Congress as they negotiate both the potential for higher corporate tax rates and the potential for higher capital gains rates,\" Kostin added.</p>\n<p>Kostin's 2021 price target for the S&amp;P 500 is 4,300, a shade below its current level of 4,352.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>40 of the hottest stocks in the market so far in 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n40 of the hottest stocks in the market so far in 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/40-of-the-hottest-stocks-in-the-market-so-far-in-2021-123439153.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It has been a great year for the stock prices of some very well-known companies, and in a few cases surprisingly so.\nThe broader market's performance hasn't been too shabby, either. So far on the year...</p>\n\n<a href=\"https://finance.yahoo.com/news/40-of-the-hottest-stocks-in-the-market-so-far-in-2021-123439153.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/40-of-the-hottest-stocks-in-the-market-so-far-in-2021-123439153.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149507863","content_text":"It has been a great year for the stock prices of some very well-known companies, and in a few cases surprisingly so.\nThe broader market's performance hasn't been too shabby, either. So far on the year, the S&P 500 (^GSPC) has rallied 16% — with an 8.5% gain alone in the second quarter. The 40 best-performing stocks in the S&P 500 have notched a median gain of 60.4%, according to data from Goldman Sachs (GS).\nSuch double-digit appreciation on the S&P 500 comes despite several formidable headwinds swirling around, ranging from the Archegos Capital Management blowup in the winter to threats of higher taxes from the Biden administration to a clear change in tone on monetary policy from the Federal Reserve.\nThe top three best-performing sectors of the S&P 500 include energy (+45%), financials (+25%) and real estate (+24%).\nUnderneath the hood of the S&P 500, there have been a host of eye-popping gains as seen below in a new chart out of Goldman Sachs.\nIn the not-so-surprising category, there are 69.1% and 49.1% respective increases in the stock prices of Ford (F) and General Motors (GM). Both auto giants have benefited from strong pricing power amid vehicle shortages brought on by the yawning semiconductor shortage. Each has also been praised by Wall Street for aggressive pushes into electric vehicles as they look to challenge EV leader Tesla (TSLA).\nThe 53.3% surge in shares of Nvidia also looks to be rather deserved. Analysts have clung onto the chip-maker's stock this year amid strong results for its gaming chips and crypto mining exposure. The impending $40 billion deal for Arm is also seen as a game-changer for the company's future earnings power.\nNot too shabby of year for the stock prices of many companies.Goldman Sachs\nAs for the surprises in the market, there are several that standout.\nFor starters, Gap's shares have shot up a mind-bending 68% year to date on optimism over Kanye West's new apparel collection for the retailer and people buying clothes en masse for their post-pandemic lives. But, the company is still seen as a longer term market share loser by most Wall Street analysts.\nOut of the 21 sell-side analysts that cover Gap, only four rate the stock a Buy, according to Bloomberg data. A total of 14 analysts rate the stock a hold, with one coming in at a sell.\nWells Fargo (WFC) shares are shockingly up 50.8% this year as new CEO Charlie Scharf struggles to stabilize the company after its highly publicized account fraud scandal. The bank is generally viewed on the Street as not as fundamentally sound as rivals JPMorgan (JPM) and Bank of America (BAC).\nMeanwhile, five of the top 10 best-performing stocks in the S&P 500 this year are energy companies. While the names appear to be tracking the 45% rise in oil prices this year, the gains are somewhat surprising given the increased ESG focus among institutional investors. ExxonMobil is interestingly up 57.9% this year even as it battles through a board shakeup, a bloated cost structure and questions about the leadership of its CEO Darren Woods.\nWhether the S&P 500 could continue its blistering pace evidenced in the first half is anyone's guess. The aforementioned headwinds to stock prices are unlikely going anywhere, and in fact could blow harder, some analysts say.\n\"You've got two big headwinds facing the market in the next six months that I think is likely to restrain the appreciation. The first issue is higher rates [interest]. The idea of higher rates is typically associated with some lower valuations,\" Goldman Sachs chief U.S. equity strategist David Kostin said on Yahoo Finance Live.\nKostin says the other issue facing investors comes at the hands of lawmakers.\n\"The second issue is tax reform. We are sitting here today literally in the middle of the year and that is likely to be the dominant topic policy-wise in the next several months in Congress as they negotiate both the potential for higher corporate tax rates and the potential for higher capital gains rates,\" Kostin added.\nKostin's 2021 price target for the S&P 500 is 4,300, a shade below its current level of 4,352.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".SPX":0.9,"BAC":0.6,"F":0.6,"ESmain":0.9,"GM":0.6,"GPS":0.6,"GS":0.9,"IVV":0.9,"JCI":0.6,"JPM":0.6,"LB":0.6,"NVDA":0.6,"NWS":0.9,"NWS.AU":0.6,"NWSA":0.6,"NWSAL":0.6,"NWSLV.AU":0.6,"OEF":0.9,"OEX":0.9,"SDS":0.9,"SH":0.9,"SLB":0.6,"SPXU":0.9,"SPY":0.9,"SSO":0.9,"TSLA":0.6,"UPRO":0.9,"WFC":0.6,"XOM":0.6}},"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150288172,"gmtCreate":1624907534196,"gmtModify":1633947207050,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Good to see exponential stocks, but am also a little cautious when it skyrockets too soon, too much.&nbsp;","listText":"Good to see exponential stocks, but am also a little cautious when it skyrockets too soon, too much.&nbsp;","text":"Good to see exponential stocks, but am also a little cautious when it skyrockets too soon, too much.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/150288172","repostId":"2146002845","repostType":4,"repost":{"id":"2146002845","kind":"highlight","pubTimestamp":1624866683,"share":"https://ttm.financial/m/news/2146002845?lang=&edition=full","pubTime":"2021-06-28 15:51","market":"us","language":"en","title":"These Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet","url":"https://stock-news.laohu8.com/highlight/detail?id=2146002845","media":"Motley Fool","summary":"Sales for these companies should skyrocket between 400% and 1,118% over the next four years.","content":"<p>For more than a decade, growth stocks have been all the rage on Wall Street. Historically low lending rates, dovish monetary policy, and a free-spending Capitol Hill (at least during the pandemic) have allowed fast-growing companies to thrive.</p>\n<p>Typically, it's smaller companies that generate some of the fastest sales growth, while large-cap stocks (those with market caps of at least $10 billion) grow at a more tempered pace. Larger companies are more likely to have time-tested or mature operating models, making it less common that they generate eye-popping revenue growth.</p>\n<p>However, the following large-cap stocks didn't get that memo. Each and every <a href=\"https://laohu8.com/S/AONE\">one</a> of these companies is on track to, at minimum, quintuple their sales over a four-year period, according to Wall Street's consensus revenue estimate for 2024 (or fiscal 2025). You could rightly say that these are five of the fastest-growing large-cap stocks on the planet.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ccad26103b3c97bbb65d0cad160f21b9\" tg-width=\"700\" tg-height=\"489\"><span>Image source: Getty Images.</span></p>\n<h2>Sea Limited: Implied four-year sales growth of 400%</h2>\n<p>Who said companies with market caps in excess of $100 billion can't grow like their smaller competitors? According to analysts, Singapore-based <b>Sea Limited</b> (NYSE:SE) is expected to see its full-year sales skyrocket from $4.39 billion in 2020 to about $21.9 billion in 2024. That works out to a quintupling in full-year revenue in four years.</p>\n<p>Sea's secret sauce (say that three times fast) is that it has three rapidly growing operating segments. For the moment, it's being anchored by its digital gaming operations. The company ended March with close to 649 million active users, 12.3% of which were paying to play. That's well above the industry average, and it's notably higher than the 8.9% of quarterly active users who were paying <a href=\"https://laohu8.com/S/AONE.U\">one</a> year ago.</p>\n<p>However, the superstar for this company is its e-commerce platform, Shopee. It's the top shopping app downloaded in Southeastern Asia, and it's becoming especially popular in Brazil. In the first quarter of 2021, Shopee saw $12.6 billion in gross merchandise value (GMV) purchased. For some context here, Shopee did $10.3 billion in GMV in all of 2018. Both the coronavirus pandemic and the rise of the middle class throughout Southeastern Asia is driving online purchases.</p>\n<p>Lastly, Sea has its rapidly growing digital financial services segment. More than 26 million people were paying for mobile wallet services at the end of March. Since the company targets a number of underbanked emerging markets, this digital financial services segment could be a major long-term growth driver.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Plug Power: Implied four-year sales growth of 404%</h2>\n<p>Companies focused on renewable energy solutions should be among the fastest growing this decade. Over the next four years investors will struggle to find a green-energy stock expanding quicker than hydrogen fuel-cell solutions provider <b>Plug Power</b> (NASDAQ:PLUG). After delivering $337 million in sales in 2020, Plug has guided for $1.7 billion in full-year revenue for 2024. That's a cool 404% increase, if it comes to fruition.</p>\n<p>For the time being, climate change is Plug Power's best friend. Joe Biden winning the presidency last year, coupled with Democrats regaining control of the Senate by the narrowest of margins, gives the current administration an opportunity to pass a clean energy bill. While it's unclear what a final infrastructure bill might look like, it's almost a certainty that clean vehicle solutions, such as those developed by Plug Power, will benefit.</p>\n<p>Additionally, the company secured two joint ventures just days apart in January. First, SK Group took a 10% equity stake in the company, with the duo aiming to introduce hydrogen fuel-cell-powered vehicles and hydrogen refilling stations in South Korea. A few days later, Plug landed a deal with French automaker <b>Renault</b> that'll see the two go after Europe's light commercial vehicle market. Both joint ventures should result in Plug Power's orders catapulting higher.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8db519446ea812ab6b8023df3f60f0c3\" tg-width=\"700\" tg-height=\"393\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: Implied four-year sales growth of 559%</h2>\n<p>The cloud computing space is home to dozens of fast-growing companies, none of which appear to be increasing its sales faster than cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). In fiscal 2021, Snowflake's sales grew by 124% to $592 million. But based on Wall Street's consensus for fiscal 2025, it's on track to generate $3.9 billion in revenue. This would represent a four-year increase of 559%.</p>\n<p>What makes Snowflake so special is the company's competitive advantages. For example, it's shunned subscriptions in favor of a pay-as-you-go operating model. Customers pay for the amount of data they store and the number of Snowflake Compute Credits used. This allows the company's clients to keep better tabs on their expenses.</p>\n<p>Also, since Snowflake's solutions are built atop the most popular cloud infrastructure platforms, customers can share data seamlessly, even across competing services.</p>\n<p>Though it's the fastest-growing cloud stock, Snowflake is also one of the priciest. It's currently valued at 67 times projected sales for fiscal 2022 and roughly 19 times estimated sales four years from now. But if the company makes good on its fiscal 2029 outlook of $10 billion in product sales, paying this premium may be well worth it.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\"><span>The NIO EC6 EV crossover SUV. Image source: NIO.</span></p>\n<h2>NIO: Implied four-year sales growth of 561%</h2>\n<p>Another absolute beast of a growth trend this decade is the rise of electric vehicles (EV). Though <b>Tesla</b>&nbsp;and the U.S. EV market tend to get a lot of attention, the biggest opportunity is actually China. That's why <b>NIO</b> (NYSE:NIO) finds itself as one of the fastest-growing large-cap stocks on the planet. If all goes well, full-year sales can catapult from about $2.5 billion in 2020 to $16.8 billion in 2024. That's a sales increase of approximately 561%.</p>\n<p>Despite a global chip shortage, NIO has shown Wall Street that it can effectively scale its production. After delivering 20,060 vehicles in the first quarter, the company is on pace to deliver between 21,000 and 22,000 EVs in the second quarter. Once global chip supply issues are resolved, NIO will look to boost its annual delivery capacity to around 150,000 EVs.</p>\n<p>For NIO, innovation is extremely important. It's been introducing one new vehicle each year, with the sportier EC6 crossover SUV hitting showrooms last summer. It's quickly become a hit with EV buyers.</p>\n<p>Additionally, NIO introduced a battery-as-a-service program. For a monthly fee, this subscription service allows buyers to replace or upgrade their vehicle's batteries. It also reduces the initial purchase price of the vehicle. Though NIO is giving up near-term margin by reducing the purchase price of its EVs, it's keeping buyers loyal and generating very high margin residual service revenue.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/849b25e21ebbcd8fae1e28f0543300db\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Novavax: Implied four-year sales growth of 1,118%</h2>\n<p>The crème de la crème of fast-growing large-cap companies is biotech stock <b>Novavax</b> (NASDAQ:NVAX). Following a pandemic-ravaged year where it brought in $476 million in sales, Wall Street is looking for Novavax to generate $5.8 billion in annual revenue in 2024. That's your run-of-the-mill sales increase of 1,118% over the coming four years.</p>\n<p>As you may have rightly guessed, Novavax's core catalyst is a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, NVX-CoV2373 (these scientific names just roll off the tongue), demonstrated nearly 90% efficacy in a large U.K. study, and recently reported a 90.4% trial efficacy in the United States.&nbsp; With efficacy rates this high, Novavax could potentially displace <b>Johnson &amp; Johnson</b>'s single-dose vaccine, which offered an efficacy of 72%.</p>\n<p>Though you'd think this was a cut-and-dried success story, Novavax has delayed its emergency-use authorization filings in Europe, the U.S., and U.K. until the third quarter, and it likely won't be at full production capacity till the fourth quarter. This waiting game has caused wild vacillations in Novavax's share price of late.</p>\n<p>Nevertheless, Novavax has a good chance of being one of the primary COVID-19 vaccines used in emerging markets, and it could become a key player if booster shots become necessary.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 15:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/27/5-of-fastest-growing-large-cap-stocks-on-planet/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For more than a decade, growth stocks have been all the rage on Wall Street. Historically low lending rates, dovish monetary policy, and a free-spending Capitol Hill (at least during the pandemic) ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/27/5-of-fastest-growing-large-cap-stocks-on-planet/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd","NIO":"蔚来","NVAX":"诺瓦瓦克斯医药","SNOW":"Snowflake","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/27/5-of-fastest-growing-large-cap-stocks-on-planet/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146002845","content_text":"For more than a decade, growth stocks have been all the rage on Wall Street. Historically low lending rates, dovish monetary policy, and a free-spending Capitol Hill (at least during the pandemic) have allowed fast-growing companies to thrive.\nTypically, it's smaller companies that generate some of the fastest sales growth, while large-cap stocks (those with market caps of at least $10 billion) grow at a more tempered pace. Larger companies are more likely to have time-tested or mature operating models, making it less common that they generate eye-popping revenue growth.\nHowever, the following large-cap stocks didn't get that memo. Each and every one of these companies is on track to, at minimum, quintuple their sales over a four-year period, according to Wall Street's consensus revenue estimate for 2024 (or fiscal 2025). You could rightly say that these are five of the fastest-growing large-cap stocks on the planet.\nImage source: Getty Images.\nSea Limited: Implied four-year sales growth of 400%\nWho said companies with market caps in excess of $100 billion can't grow like their smaller competitors? According to analysts, Singapore-based Sea Limited (NYSE:SE) is expected to see its full-year sales skyrocket from $4.39 billion in 2020 to about $21.9 billion in 2024. That works out to a quintupling in full-year revenue in four years.\nSea's secret sauce (say that three times fast) is that it has three rapidly growing operating segments. For the moment, it's being anchored by its digital gaming operations. The company ended March with close to 649 million active users, 12.3% of which were paying to play. That's well above the industry average, and it's notably higher than the 8.9% of quarterly active users who were paying one year ago.\nHowever, the superstar for this company is its e-commerce platform, Shopee. It's the top shopping app downloaded in Southeastern Asia, and it's becoming especially popular in Brazil. In the first quarter of 2021, Shopee saw $12.6 billion in gross merchandise value (GMV) purchased. For some context here, Shopee did $10.3 billion in GMV in all of 2018. Both the coronavirus pandemic and the rise of the middle class throughout Southeastern Asia is driving online purchases.\nLastly, Sea has its rapidly growing digital financial services segment. More than 26 million people were paying for mobile wallet services at the end of March. Since the company targets a number of underbanked emerging markets, this digital financial services segment could be a major long-term growth driver.\nImage source: Getty Images.\nPlug Power: Implied four-year sales growth of 404%\nCompanies focused on renewable energy solutions should be among the fastest growing this decade. Over the next four years investors will struggle to find a green-energy stock expanding quicker than hydrogen fuel-cell solutions provider Plug Power (NASDAQ:PLUG). After delivering $337 million in sales in 2020, Plug has guided for $1.7 billion in full-year revenue for 2024. That's a cool 404% increase, if it comes to fruition.\nFor the time being, climate change is Plug Power's best friend. Joe Biden winning the presidency last year, coupled with Democrats regaining control of the Senate by the narrowest of margins, gives the current administration an opportunity to pass a clean energy bill. While it's unclear what a final infrastructure bill might look like, it's almost a certainty that clean vehicle solutions, such as those developed by Plug Power, will benefit.\nAdditionally, the company secured two joint ventures just days apart in January. First, SK Group took a 10% equity stake in the company, with the duo aiming to introduce hydrogen fuel-cell-powered vehicles and hydrogen refilling stations in South Korea. A few days later, Plug landed a deal with French automaker Renault that'll see the two go after Europe's light commercial vehicle market. Both joint ventures should result in Plug Power's orders catapulting higher.\nImage source: Getty Images.\nSnowflake: Implied four-year sales growth of 559%\nThe cloud computing space is home to dozens of fast-growing companies, none of which appear to be increasing its sales faster than cloud data-warehousing company Snowflake (NYSE:SNOW). In fiscal 2021, Snowflake's sales grew by 124% to $592 million. But based on Wall Street's consensus for fiscal 2025, it's on track to generate $3.9 billion in revenue. This would represent a four-year increase of 559%.\nWhat makes Snowflake so special is the company's competitive advantages. For example, it's shunned subscriptions in favor of a pay-as-you-go operating model. Customers pay for the amount of data they store and the number of Snowflake Compute Credits used. This allows the company's clients to keep better tabs on their expenses.\nAlso, since Snowflake's solutions are built atop the most popular cloud infrastructure platforms, customers can share data seamlessly, even across competing services.\nThough it's the fastest-growing cloud stock, Snowflake is also one of the priciest. It's currently valued at 67 times projected sales for fiscal 2022 and roughly 19 times estimated sales four years from now. But if the company makes good on its fiscal 2029 outlook of $10 billion in product sales, paying this premium may be well worth it.\nThe NIO EC6 EV crossover SUV. Image source: NIO.\nNIO: Implied four-year sales growth of 561%\nAnother absolute beast of a growth trend this decade is the rise of electric vehicles (EV). Though Tesla and the U.S. EV market tend to get a lot of attention, the biggest opportunity is actually China. That's why NIO (NYSE:NIO) finds itself as one of the fastest-growing large-cap stocks on the planet. If all goes well, full-year sales can catapult from about $2.5 billion in 2020 to $16.8 billion in 2024. That's a sales increase of approximately 561%.\nDespite a global chip shortage, NIO has shown Wall Street that it can effectively scale its production. After delivering 20,060 vehicles in the first quarter, the company is on pace to deliver between 21,000 and 22,000 EVs in the second quarter. Once global chip supply issues are resolved, NIO will look to boost its annual delivery capacity to around 150,000 EVs.\nFor NIO, innovation is extremely important. It's been introducing one new vehicle each year, with the sportier EC6 crossover SUV hitting showrooms last summer. It's quickly become a hit with EV buyers.\nAdditionally, NIO introduced a battery-as-a-service program. For a monthly fee, this subscription service allows buyers to replace or upgrade their vehicle's batteries. It also reduces the initial purchase price of the vehicle. Though NIO is giving up near-term margin by reducing the purchase price of its EVs, it's keeping buyers loyal and generating very high margin residual service revenue.\nImage source: Getty Images.\nNovavax: Implied four-year sales growth of 1,118%\nThe crème de la crème of fast-growing large-cap companies is biotech stock Novavax (NASDAQ:NVAX). Following a pandemic-ravaged year where it brought in $476 million in sales, Wall Street is looking for Novavax to generate $5.8 billion in annual revenue in 2024. That's your run-of-the-mill sales increase of 1,118% over the coming four years.\nAs you may have rightly guessed, Novavax's core catalyst is a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, NVX-CoV2373 (these scientific names just roll off the tongue), demonstrated nearly 90% efficacy in a large U.K. study, and recently reported a 90.4% trial efficacy in the United States.  With efficacy rates this high, Novavax could potentially displace Johnson & Johnson's single-dose vaccine, which offered an efficacy of 72%.\nThough you'd think this was a cut-and-dried success story, Novavax has delayed its emergency-use authorization filings in Europe, the U.S., and U.K. until the third quarter, and it likely won't be at full production capacity till the fourth quarter. This waiting game has caused wild vacillations in Novavax's share price of late.\nNevertheless, Novavax has a good chance of being one of the primary COVID-19 vaccines used in emerging markets, and it could become a key player if booster shots become necessary.","news_type":1,"symbols_score_info":{"NIO":0.9,"NVAX":0.9,"PLUG":0.9,"SE":0.9,"SNOW":0.9}},"isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157552513,"gmtCreate":1625593929532,"gmtModify":1633939268114,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>&nbsp;hopefully it goes up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>&nbsp;hopefully it goes up!&nbsp;","text":"$NIO Inc.(NIO)$ hopefully it goes up!","images":[{"img":"https://static.tigerbbs.com/cef51ca97f74045e87b17d141370f007","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/157552513","isVote":1,"tweetType":1,"viewCount":653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":165620137,"gmtCreate":1624131400129,"gmtModify":1634010459395,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Hopefully travel picks up soon!&nbsp;","listText":"Hopefully travel picks up soon!&nbsp;","text":"Hopefully travel picks up soon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/165620137","repostId":"2144086770","repostType":4,"repost":{"id":"2144086770","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624062134,"share":"https://ttm.financial/m/news/2144086770?lang=&edition=full","pubTime":"2021-06-19 08:22","market":"us","language":"en","title":"Largest Boeing 737 MAX model takes off on maiden flight","url":"https://stock-news.laohu8.com/highlight/detail?id=2144086770","media":"Reuters","summary":"RENTON, Wash., June 18 (Reuters) - Boeing Co's 737 MAX 10, the largest member of its best-selling si","content":"<p>RENTON, Wash., June 18 (Reuters) - Boeing Co's 737 MAX 10, the largest member of its best-selling single-aisle airplane family, took off on its maiden flight on Friday, in a further step toward recovering from the safety grounding of a smaller model.</p>\n<p>The plane completed a roughly 2-1/2-hour flight over Washington State, returning to Renton Municipal Airport near Seattle at 12:38 p.m.</p>\n<p>The first flight heralds months of testing and safety certification work before the jet is expected to enter service in 2023.</p>\n<p>In an unusual departure from the PR buzz surrounding first flights, the event was kept low-key as Boeing tries to navigate overlapping crises caused by a 20-month grounding in the wake of two crashes and the COVID-19 pandemic.</p>\n<p>Boeing's 230-seat 737-10 is designed to close the gap between its 178-to-220-seat 737-9, and Airbus's 185-to-240-seat A321neo, which dominates the top end of the narrowbody jet market, worth some $3.5 trillion over 20 years.</p>\n<p>However, the market opportunity for the 737 MAX 10 is constrained by the jet's range of about 3,300 nautical miles (6,100 km), which falls short of the A321neo's roughly 4,000 nm.</p>\n<p>Boeing must also complete safety certification of the plane under a tougher regulatory climate following two fatal crashes of a smaller 737 MAX version grounded the model for nearly two years - with a safety ban still in place in China.</p>\n<p>Boeing has carried out design and training changes on the MAX family, which returned to U.S. operations in December.</p>\n<p>Boeing Commercial Airplanes CEO Stan Deal said the company is producing about 16 737 MAX jets a month at its Renton factory.</p>\n<p>Boeing is working on safety enhancements for the 737 MAX 10, including for its air data indication system and adding a third cockpit indication requested by European regulators of the \"angle of attack,\" a parameter needed to avoid stalling or losing lift. Deal’s comments were provided to the media via a pool reporter inside a Boeing aircraft delivery center.</p>\n<p>\"We're going to take our time on this certification,\" Deal said.</p>\n<p>While the smaller MAX 8 is Boeing's fastest-selling jet, slow sales of the MAX 9 and 10 models have put Boeing at a disadvantage to the A321neo.</p>\n<p>Boeing has abandoned plans to tinker with the 737 MAX 10 design, but is weighing a bolder plan to replace the single-aisle 757, which overlaps with the top end of the MAX family.</p>\n<p>Even so, Boeing says it is confident in the MAX 10, and it is stepping up efforts to sell more of the jet, with key targets, including Ireland's Ryanair .</p>\n<p>Customers include United Airlines with 100 on order. Although sources say United is weighing a new order for at least 100 or even up to 200 MAX, its requirement for large single-aisles will be served by Airbus - reinforcing the market split.</p>\n<p>The flight, watched by dozens of employees but virtually no visitors as Boeing sought to downplay the event, showcased a revamped landing gear system illustrating an industry battle to squeeze as much mileage as possible out of the current generation of single-aisles.</p>\n<p>It raises the landing gear's height during take-off and landing, a design needed to compensate for the MAX 10's extra length and prevent the tail scraping the runway on take-off.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Largest Boeing 737 MAX model takes off on maiden flight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLargest Boeing 737 MAX model takes off on maiden flight\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-19 08:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RENTON, Wash., June 18 (Reuters) - Boeing Co's 737 MAX 10, the largest member of its best-selling single-aisle airplane family, took off on its maiden flight on Friday, in a further step toward recovering from the safety grounding of a smaller model.</p>\n<p>The plane completed a roughly 2-1/2-hour flight over Washington State, returning to Renton Municipal Airport near Seattle at 12:38 p.m.</p>\n<p>The first flight heralds months of testing and safety certification work before the jet is expected to enter service in 2023.</p>\n<p>In an unusual departure from the PR buzz surrounding first flights, the event was kept low-key as Boeing tries to navigate overlapping crises caused by a 20-month grounding in the wake of two crashes and the COVID-19 pandemic.</p>\n<p>Boeing's 230-seat 737-10 is designed to close the gap between its 178-to-220-seat 737-9, and Airbus's 185-to-240-seat A321neo, which dominates the top end of the narrowbody jet market, worth some $3.5 trillion over 20 years.</p>\n<p>However, the market opportunity for the 737 MAX 10 is constrained by the jet's range of about 3,300 nautical miles (6,100 km), which falls short of the A321neo's roughly 4,000 nm.</p>\n<p>Boeing must also complete safety certification of the plane under a tougher regulatory climate following two fatal crashes of a smaller 737 MAX version grounded the model for nearly two years - with a safety ban still in place in China.</p>\n<p>Boeing has carried out design and training changes on the MAX family, which returned to U.S. operations in December.</p>\n<p>Boeing Commercial Airplanes CEO Stan Deal said the company is producing about 16 737 MAX jets a month at its Renton factory.</p>\n<p>Boeing is working on safety enhancements for the 737 MAX 10, including for its air data indication system and adding a third cockpit indication requested by European regulators of the \"angle of attack,\" a parameter needed to avoid stalling or losing lift. Deal’s comments were provided to the media via a pool reporter inside a Boeing aircraft delivery center.</p>\n<p>\"We're going to take our time on this certification,\" Deal said.</p>\n<p>While the smaller MAX 8 is Boeing's fastest-selling jet, slow sales of the MAX 9 and 10 models have put Boeing at a disadvantage to the A321neo.</p>\n<p>Boeing has abandoned plans to tinker with the 737 MAX 10 design, but is weighing a bolder plan to replace the single-aisle 757, which overlaps with the top end of the MAX family.</p>\n<p>Even so, Boeing says it is confident in the MAX 10, and it is stepping up efforts to sell more of the jet, with key targets, including Ireland's Ryanair .</p>\n<p>Customers include United Airlines with 100 on order. Although sources say United is weighing a new order for at least 100 or even up to 200 MAX, its requirement for large single-aisles will be served by Airbus - reinforcing the market split.</p>\n<p>The flight, watched by dozens of employees but virtually no visitors as Boeing sought to downplay the event, showcased a revamped landing gear system illustrating an industry battle to squeeze as much mileage as possible out of the current generation of single-aisles.</p>\n<p>It raises the landing gear's height during take-off and landing, a design needed to compensate for the MAX 10's extra length and prevent the tail scraping the runway on take-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144086770","content_text":"RENTON, Wash., June 18 (Reuters) - Boeing Co's 737 MAX 10, the largest member of its best-selling single-aisle airplane family, took off on its maiden flight on Friday, in a further step toward recovering from the safety grounding of a smaller model.\nThe plane completed a roughly 2-1/2-hour flight over Washington State, returning to Renton Municipal Airport near Seattle at 12:38 p.m.\nThe first flight heralds months of testing and safety certification work before the jet is expected to enter service in 2023.\nIn an unusual departure from the PR buzz surrounding first flights, the event was kept low-key as Boeing tries to navigate overlapping crises caused by a 20-month grounding in the wake of two crashes and the COVID-19 pandemic.\nBoeing's 230-seat 737-10 is designed to close the gap between its 178-to-220-seat 737-9, and Airbus's 185-to-240-seat A321neo, which dominates the top end of the narrowbody jet market, worth some $3.5 trillion over 20 years.\nHowever, the market opportunity for the 737 MAX 10 is constrained by the jet's range of about 3,300 nautical miles (6,100 km), which falls short of the A321neo's roughly 4,000 nm.\nBoeing must also complete safety certification of the plane under a tougher regulatory climate following two fatal crashes of a smaller 737 MAX version grounded the model for nearly two years - with a safety ban still in place in China.\nBoeing has carried out design and training changes on the MAX family, which returned to U.S. operations in December.\nBoeing Commercial Airplanes CEO Stan Deal said the company is producing about 16 737 MAX jets a month at its Renton factory.\nBoeing is working on safety enhancements for the 737 MAX 10, including for its air data indication system and adding a third cockpit indication requested by European regulators of the \"angle of attack,\" a parameter needed to avoid stalling or losing lift. Deal’s comments were provided to the media via a pool reporter inside a Boeing aircraft delivery center.\n\"We're going to take our time on this certification,\" Deal said.\nWhile the smaller MAX 8 is Boeing's fastest-selling jet, slow sales of the MAX 9 and 10 models have put Boeing at a disadvantage to the A321neo.\nBoeing has abandoned plans to tinker with the 737 MAX 10 design, but is weighing a bolder plan to replace the single-aisle 757, which overlaps with the top end of the MAX family.\nEven so, Boeing says it is confident in the MAX 10, and it is stepping up efforts to sell more of the jet, with key targets, including Ireland's Ryanair .\nCustomers include United Airlines with 100 on order. Although sources say United is weighing a new order for at least 100 or even up to 200 MAX, its requirement for large single-aisles will be served by Airbus - reinforcing the market split.\nThe flight, watched by dozens of employees but virtually no visitors as Boeing sought to downplay the event, showcased a revamped landing gear system illustrating an industry battle to squeeze as much mileage as possible out of the current generation of single-aisles.\nIt raises the landing gear's height during take-off and landing, a design needed to compensate for the MAX 10's extra length and prevent the tail scraping the runway on take-off.","news_type":1,"symbols_score_info":{"BA":0.9}},"isVote":1,"tweetType":1,"viewCount":422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142937900,"gmtCreate":1626118116600,"gmtModify":1631889147652,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;keep rising!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;keep rising!!&nbsp;","text":"$Tesla Motors(TSLA)$ keep rising!!","images":[{"img":"https://static.tigerbbs.com/6088282f18a37677fc335ad1902c4ee6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/142937900","isVote":1,"tweetType":1,"viewCount":1967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":127922002,"gmtCreate":1624825493706,"gmtModify":1633948391450,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Reputable stocks worth considering!&nbsp;","listText":"Reputable stocks worth considering!&nbsp;","text":"Reputable stocks worth considering!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/127922002","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","kind":"highlight","pubTimestamp":1624755315,"share":"https://ttm.financial/m/news/2146090006?lang=&edition=full","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","BRK.A":"伯克希尔","AMZN":"亚马逊","MA":"万事达","BRK.B":"伯克希尔B","BAC":"美国银行","TEVA":"梯瓦制药"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1,"symbols_score_info":{"AMZN":0.9,"BAC":0.9,"BMY":0.9,"BRK.A":0.9,"BRK.B":0.9,"MA":0.9,"TEVA":0.9}},"isVote":1,"tweetType":1,"viewCount":499,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159706623,"gmtCreate":1624978883562,"gmtModify":1633946230820,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Besides these 2, are there more stocks to consider?&nbsp;","listText":"Besides these 2, are there more stocks to consider?&nbsp;","text":"Besides these 2, are there more stocks to consider?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/159706623","repostId":"2146388793","repostType":4,"repost":{"id":"2146388793","kind":"highlight","pubTimestamp":1624959775,"share":"https://ttm.financial/m/news/2146388793?lang=&edition=full","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1,"symbols_score_info":{"MRNA":0.9,"NVDA":0.9}},"isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149876016,"gmtCreate":1625718310035,"gmtModify":1633938032523,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.&nbsp;","listText":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.&nbsp;","text":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/149876016","repostId":"2149365051","repostType":4,"repost":{"id":"2149365051","kind":"highlight","pubTimestamp":1625648700,"share":"https://ttm.financial/m/news/2149365051?lang=&edition=full","pubTime":"2021-07-07 17:05","market":"us","language":"en","title":"3 Biotechs to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=2149365051","media":"Motley Fool","summary":"Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.","content":"<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth.&nbsp;</p>\n<p>Avoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6bccd5c36f3f76148be467937b9b6293\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>1. Cel-Sci</h2>\n<p>Sometimes, <a href=\"https://laohu8.com/S/AONE\">one</a> is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after <a href=\"https://laohu8.com/S/AONE.U\">one</a>'s cover is blown.&nbsp;</p>\n<p>Take the case of&nbsp;<b>Cel-Sci&nbsp;</b>(NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.</p>\n<p>It's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"</p>\n<p>The data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.</p>\n<p>It's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.</p>\n<p>Before the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever).&nbsp;</p>\n<h2>2. CytoDyn&nbsp;</h2>\n<p><b>CytoDyn</b> (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies.&nbsp;</p>\n<p>In response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines.&nbsp;</p>\n<p>It's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.</p>\n<p>I wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.</p>\n<p>At the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders.&nbsp;</p>\n<h2>3. Northwest Biotherapeutics&nbsp;</h2>\n<p><b>Northwest Biotherapeutics</b>&nbsp;(OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies.&nbsp;</p>\n<p>The company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.</p>\n<p>The study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.</p>\n<p>The company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.</p>\n<p>Last October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.</p>\n<p>Shareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotechs to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotechs to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 17:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2149365051","content_text":"Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth. \nAvoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from. \nImage source: Getty Images.\n1. Cel-Sci\nSometimes, one is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after one's cover is blown. \nTake the case of Cel-Sci (NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.\nIt's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"\nThe data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.\nIt's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.\nBefore the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever). \n2. CytoDyn \nCytoDyn (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies. \nIn response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines. \nIt's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.\nI wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.\nAt the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders. \n3. Northwest Biotherapeutics \nNorthwest Biotherapeutics (OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies. \nThe company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.\nThe study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.\nThe company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.\nLast October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.\nShareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.","news_type":1,"symbols_score_info":{"CVM":0.9,"CYDY":0.9,"NWBO":0.9}},"isVote":1,"tweetType":1,"viewCount":430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154877681,"gmtCreate":1625510334443,"gmtModify":1633940144150,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"The true strength&nbsp;of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!&nbsp;","listText":"The true strength&nbsp;of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!&nbsp;","text":"The true strength of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154877681","repostId":"1157317474","repostType":4,"isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158539514,"gmtCreate":1625154535338,"gmtModify":1631888920994,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>&nbsp;hopefully it keeps going up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>&nbsp;hopefully it keeps going up!&nbsp;","text":"$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$ hopefully it keeps going up!","images":[{"img":"https://static.tigerbbs.com/6c1bd42cf964b85c81960a4e99156b8b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158539514","isVote":1,"tweetType":1,"viewCount":454,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128883710,"gmtCreate":1624510097330,"gmtModify":1631884323408,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Hope it continues to go up!&nbsp;","listText":"Hope it continues to go up!&nbsp;","text":"Hope it continues to go up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128883710","repostId":"1176854050","repostType":4,"isVote":1,"tweetType":1,"viewCount":242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":110486826,"gmtCreate":1622488094065,"gmtModify":1634101180963,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Hmmm.&nbsp;","listText":"Hmmm.&nbsp;","text":"Hmmm.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/110486826","repostId":"1133890180","repostType":4,"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802868778,"gmtCreate":1627755422494,"gmtModify":1631884081594,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's&nbsp;the former!&nbsp;","listText":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's&nbsp;the former!&nbsp;","text":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's the former!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/802868778","repostId":"2155013045","repostType":4,"repost":{"id":"2155013045","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627642860,"share":"https://ttm.financial/m/news/2155013045?lang=&edition=full","pubTime":"2021-07-30 19:01","market":"us","language":"en","title":"P&G beats quarterly sales estimates, warns of cost pressures","url":"https://stock-news.laohu8.com/highlight/detail?id=2155013045","media":"Reuters","summary":"July 30 (Reuters) - Procter & Gamble Co reported fourth-quarter sales on Friday that beat analysts' ","content":"<p>July 30 (Reuters) - Procter &amp; Gamble Co&nbsp;reported fourth-quarter sales on Friday that beat analysts' estimates, but warned that rising commodity and freight costs would take a $1.9 billion bite out of its earnings this year.</p>\n<p>The vaccine-aided easing of COVID-19 restrictions in the United States and parts of Europe helped the company post an 11% increase in sales at its beauty segment in the reported quarter, as consumers returning to social events, spent more on personal care products.</p>\n<p>Procter &amp; Gamble said net sales rose 7% to $18.95 billion in the quarter ended June 30, compared with estimates of $18.41 billion, according to IBES data from Refinitiv.</p>\n<p>The company forecast fiscal 2022 core earnings per share to rise between 3% and 6%, and sales to increase in the 2% to 4% range.</p>\n<p>Late on Thursday, the Tide detergent maker named Chief Operating Officer Jon Moeller as its new CEO, replacing David Taylor, who will become executive chairman on Nov. 1.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>P&G beats quarterly sales estimates, warns of cost pressures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nP&G beats quarterly sales estimates, warns of cost pressures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-30 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 30 (Reuters) - Procter &amp; Gamble Co&nbsp;reported fourth-quarter sales on Friday that beat analysts' estimates, but warned that rising commodity and freight costs would take a $1.9 billion bite out of its earnings this year.</p>\n<p>The vaccine-aided easing of COVID-19 restrictions in the United States and parts of Europe helped the company post an 11% increase in sales at its beauty segment in the reported quarter, as consumers returning to social events, spent more on personal care products.</p>\n<p>Procter &amp; Gamble said net sales rose 7% to $18.95 billion in the quarter ended June 30, compared with estimates of $18.41 billion, according to IBES data from Refinitiv.</p>\n<p>The company forecast fiscal 2022 core earnings per share to rise between 3% and 6%, and sales to increase in the 2% to 4% range.</p>\n<p>Late on Thursday, the Tide detergent maker named Chief Operating Officer Jon Moeller as its new CEO, replacing David Taylor, who will become executive chairman on Nov. 1.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155013045","content_text":"July 30 (Reuters) - Procter & Gamble Co reported fourth-quarter sales on Friday that beat analysts' estimates, but warned that rising commodity and freight costs would take a $1.9 billion bite out of its earnings this year.\nThe vaccine-aided easing of COVID-19 restrictions in the United States and parts of Europe helped the company post an 11% increase in sales at its beauty segment in the reported quarter, as consumers returning to social events, spent more on personal care products.\nProcter & Gamble said net sales rose 7% to $18.95 billion in the quarter ended June 30, compared with estimates of $18.41 billion, according to IBES data from Refinitiv.\nThe company forecast fiscal 2022 core earnings per share to rise between 3% and 6%, and sales to increase in the 2% to 4% range.\nLate on Thursday, the Tide detergent maker named Chief Operating Officer Jon Moeller as its new CEO, replacing David Taylor, who will become executive chairman on Nov. 1.","news_type":1,"symbols_score_info":{"PG":0.9}},"isVote":1,"tweetType":1,"viewCount":1523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171151724,"gmtCreate":1626723016068,"gmtModify":1631889147616,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Too late to enter?&nbsp;","listText":"Too late to enter?&nbsp;","text":"Too late to enter?","images":[{"img":"https://static.tigerbbs.com/42219fdf52209378b59da8da9140fbdb","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171151724","isVote":1,"tweetType":1,"viewCount":1835,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":179274848,"gmtCreate":1626544274584,"gmtModify":1631889147627,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Recent sharp increase. Will it keep going up?&nbsp;","listText":"Recent sharp increase. Will it keep going up?&nbsp;","text":"Recent sharp increase. Will it keep going up?","images":[{"img":"https://static.tigerbbs.com/994ed0ff59981c6ffb17b3bbe1d409b6","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179274848","isVote":1,"tweetType":1,"viewCount":1153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148770097,"gmtCreate":1626032993819,"gmtModify":1631889147676,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;still not going up as much as I hope. Keep rising, tesla!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;still not going up as much as I hope. Keep rising, tesla!&nbsp;","text":"$Tesla Motors(TSLA)$ still not going up as much as I hope. Keep rising, tesla!","images":[{"img":"https://static.tigerbbs.com/da298c293b298102ce18978879e354d0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148770097","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143417632,"gmtCreate":1625808852926,"gmtModify":1631888361155,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Agree on the well explained part.&nbsp;//<a href=\"https://laohu8.com/U/3575196385895354\">@Cedric77</a>: Great article! Well explained on current down turn.&nbsp;","listText":"Agree on the well explained part.&nbsp;//<a href=\"https://laohu8.com/U/3575196385895354\">@Cedric77</a>: Great article! Well explained on current down turn.&nbsp;","text":"Agree on the well explained part. //@Cedric77: Great article! Well explained on current down turn.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143417632","repostId":"1162204971","repostType":4,"isVote":1,"tweetType":1,"viewCount":447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123654712,"gmtCreate":1624422278736,"gmtModify":1634006331541,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Will be good if it does, won't it?&nbsp;","listText":"Will be good if it does, won't it?&nbsp;","text":"Will be good if it does, won't it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123654712","repostId":"1186919064","repostType":2,"isVote":1,"tweetType":1,"viewCount":326,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169705617,"gmtCreate":1623850084139,"gmtModify":1631884324562,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Hope it brings Starbucks to the next level of success!&nbsp;","listText":"Hope it brings Starbucks to the next level of success!&nbsp;","text":"Hope it brings Starbucks to the next level of success!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169705617","repostId":"2143763826","repostType":2,"repost":{"id":"2143763826","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1623787501,"share":"https://ttm.financial/m/news/2143763826?lang=&edition=full","pubTime":"2021-06-16 04:05","market":"us","language":"en","title":"Starbucks Says John Culver Promoted To Group President, North America And Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2143763826","media":"T-Reuters","summary":"June 15 (Reuters) - Starbucks Corp : :Starbucks Says John Culver Promoted To Group President, North ","content":"<html><body><p>June 15 (Reuters) - Starbucks Corp <sbux.o>: :Starbucks Says John Culver Promoted To Group President, North America And Chief Operating Officer.</sbux.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Starbucks Says John Culver Promoted To Group President, North America And Chief Operating Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStarbucks Says John Culver Promoted To Group President, North America And Chief Operating Officer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-06-16 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>June 15 (Reuters) - Starbucks Corp <sbux.o>: :Starbucks Says John Culver Promoted To Group President, North America And Chief Operating Officer.</sbux.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SBUX":"星巴克"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143763826","content_text":"June 15 (Reuters) - Starbucks Corp : :Starbucks Says John Culver Promoted To Group President, North America And Chief Operating Officer.","news_type":1,"symbols_score_info":{"SBUX":1}},"isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114487624,"gmtCreate":1623088687368,"gmtModify":1634037085172,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"We shall see!&nbsp;","listText":"We shall see!&nbsp;","text":"We shall see!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114487624","repostId":"1187003503","repostType":4,"isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}